Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pathophysiol. Nov 15, 2014; 5(4): 550-559
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.550
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.550
Ref. | Year | Antibiotics | Duration | Result |
Crohn’s disease-primary therapy | ||||
Ursing et al[53] | 1982 | Metronidazole 800 mg/d | 16 wk | No difference from sulfasalazine |
Sutherland et al[54] | 1991 | Metronidazole 10 or 20 mg/kg | 16 wk | Superior to placebo (↓ CDAI), no difference in remission |
Colombel et al[55] | 1999 | Ciprofloxacin 500 mg 2 × d | 6 wk | No difference from mesalamine |
Arnold et al[56] | 2002 | Ciprofloxacin 500 mg 2 × d | 6 mo | Superior to placebo (CDAI) |
Prantera et al[57] | 1996 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 4 × d | 12 wk | No difference from prednisolone |
Greenbloom et al[58] | 1998 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 3 × d | 10 wk | Uncontrolled, 68% remission |
Leiper et al[59] | 2000 | Clarithromycin 250 mg 2 × d | 4 wk | Uncontrolled, 64% response, 48% remission |
Steinhart et al[60] | 2002 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 3 × d | 8 wk | No improvement over budesonide alone (33% vs 38% remission) |
Crohn’s disease-prevention of postsurgical relapse | ||||
Rutgeerts et al[61] | 1995 | Metronidazole 20 mg/kg | 12 wk | ↓ clinical relapse 1 yr vs placebo |
Rutgeerts et al[62] | 2005 | Ornidazole 1 g/d | 52 wk | ↓ severe endoscopic relapse vs placebo |
Ulcerative colitis-primary therapy | ||||
Turunen et al[63] | 1999 | Cipro 500 mg 2 × d | 6 mo | Superior to placebo |
Mantzaris et al[64] | 1997 | Cipro 500 mg 2 × d | 6 mo | No benefit vs placebo |
Casellas et al[65] | 1998 | Amoxicillin 1 g/ Clavulanic acid 250 mg | 5 d | ↓ mucosal IL-8 and eicosanoids vs placebo |
Turner et al[66] | 2014 | metronidazole, amoxicillin, doxycycline (Paediatrics) | Remission (46.6%) | |
Pouchitis | ||||
Shen et al[67] | 2001 | Metronidazole 20 mg/kg or Cipro 500 mg 2 × d | 6 mo | Both effective, Cipro > metronidazole |
Gionchetti et al[68] | 2000 | Cipro 500 mg 2 × d and Rifaximin 1 g 2 × d | 5 d | 89% response, 33% remission, uncontrolled |
- Citation: Bringiotti R, Ierardi E, Lovero R, Losurdo G, Leo AD, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014; 5(4): 550-559
- URL: https://www.wjgnet.com/2150-5330/full/v5/i4/550.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v5.i4.550